References
- Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005; 115: 3339–3347
- Cerutti A, Custodi P, Duranti M, Noris P, Balduini CL. Thrombopoietin (TPO) levels in patients with primary and reactive thrombocytosis. Br J Haematol 1997; 99: 281–284
- Cerutti A, Custoldi P, Duranti M, Cazzola M, Balduini CL. Circulating thrombopoietin in reactive conditions behaves like an acute-phase reactant. Clin Lab Haematol 1999; 21: 271–275
- Folman CC, Ooms M, Kuenen BB, de Jong SM, Vet VM, De Haas M, Von dem Borne AEGK. The role of thrombopoietin in post-operative thrombocytosis. Br J Haematol 2001; 114: 126–133
- Heits F, Stahl M, Ludwig D, Stange EF, Jelkmann W. Elevated serum thrombopoietin and interleukin-6 concentrations in thrombocytosis associated with inflammatory bowel disease. J Interferon Cytokine Res. 1999; 19: 757–760
- Milanovic M, Nilsson E, Jaremo P. Relationships between platelet and inflammation in rheumatoid arthritis. Clin Chim Acta 2004; 343: 237–240
- Zakynthinos SG, Papanikolaou S, Theodoridis T, Zakynthios EG, Christopoulou-Kokkinou V, Katsaris G, Mavrommatis AC. Sepsis severity is the major determinant of circulating thrombopoietin levels in septic patients. Crit Care Med 2004; 32: 1004–1010
- Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, Ludwiczek O, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: Role in inflammatory thrombocytosis. Blood 2001; 98: 2720–2724
- Burmester H, Wolber EM, Freitag P, Fandrey J, Jelkmann W. Thrombopoietin production in wild-type and interleukin-6 knockout mice with acute inflammation. J Interferon Cytokine Res 2005; 25: 407–413
- Español I, Hernández A, Cortés M, Mateo J, Pujol-Moix N. Patients with thrombocytosis have normal or slightly elevated thrombopoietin levels. Haematologica 1999; 84: 312–316
- Robinson M, Machin S, Mackie I, Harrison P. Comparison of glycocalicin, thrombopoietin and reticulated platelet measurement as markers of platelet turnover in HIV+ samples. Platelets 2001; 12: 108–113
- Steinberg MH, Kelton JG, Coller BS. Plasma glycocalicin. An aid in the classification of thrombocytopenic disorders. New Engl J Med 1987; 317: 1037–1042
- Beer JH, Buchi L, Steiner B. Glycocalicin: A new assay-the normal plasma levels and its potential usefulness in selected diseases. Blood 1994; 3: 691–702
- De Sauvage FJ, Carver-Moore K, Luoh S-M. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996; 18: 651–656
- Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004; 76: 205–213
- Harker LA, Roskos LK, Marzec UM, Carter RA, Cherry JK, Sundell B, Cheung EN, Terry D, Sheridan W. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 2000; 95: 2514–2522